Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Lieneke F M Ariëns, Daphne S Bakker, Lotte S Spekhorst, Jorien Van der Schaft, Judith L Thijs, Inge Haeck, Annebeth E Flinterman, Marijke Kamsteeg, Marie L A Schuttelaar, Marjolein S De Bruin-Weller

Research output: Contribution to journalArticleAcademicpeer-review

19 Downloads (Pure)


Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7-780.8)) to week 52 (€0.0 (0.0-211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice.

Original languageEnglish
Number of pages5
JournalActa dermato-venereologica
Issue number10
Publication statusPublished - Oct-2021


  • Adult
  • Antibodies, Monoclonal, Humanized/therapeutic use
  • Dermatitis, Atopic/diagnosis
  • Efficiency
  • Humans
  • Netherlands
  • Quality of Life
  • Registries
  • Severity of Illness Index
  • Treatment Outcome
  • Workplace

Cite this